Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02290431 · OUTCOME

Composite PharmacoKinetics (PK) of Panobinostat and Bortezomib: CL/F

Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma · Source last updated 2019-11-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
GEOMETRIC_MEAN
Unit
Litre/hour (L/h)
Interval / dispersion
Geometric Coefficient of Variation
Time frame
Predose, 0.5h, 1h, 2h, 3h, 4h 8h, 24h 48h post dose

What was measured

CL/F: The apparent total body clearance of drug from the plasma

Analysis population: PAS: Pharmacokinetic Analysis Set (PAS): The PK analysis set for PAN (PAS-PAN) consisted of all subjects with at least one evaluable PK concentration of PAN. The PK analysis set for BTZ (PAS-BTZ) consisted of all subjects with at least one evaluable PK concentration of BTZ.

Groups in this outcome

LBH589 + Bortezomib + Dexamethasone

Participants were administered LBH589 (panobinostat)in combination with bortezomib and dexamethasone 2 weeks on/1 week off.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
LBH589 + Bortezomib + Dexamethasone8

Reported measurements

PAN: C1D1

Analysis denominator · Participants

GroupSource count
LBH589 + Bortezomib + Dexamethasone8
Values in Litre/hour (L/h) · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
LBH589 + Bortezomib + Dexamethasone17215.5Not reportedNot reportedNot reported
PAN: C1D8

Analysis denominator · Participants

GroupSource count
LBH589 + Bortezomib + Dexamethasone7
Values in Litre/hour (L/h) · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
LBH589 + Bortezomib + Dexamethasone11432.7Not reportedNot reportedNot reported
BJB432: C1D1

Analysis denominator · Participants

GroupSource count
LBH589 + Bortezomib + Dexamethasone0
BJB432: C1D8

Analysis denominator · Participants

GroupSource count
LBH589 + Bortezomib + Dexamethasone0
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        15.5
        value
        172
    denoms
    1. counts
      1. group Id
        OG000
        value
        8
      units
      Participants
    title
    PAN: C1D1
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        32.7
        value
        114
    denoms
    1. counts
      1. group Id
        OG000
        value
        7
      units
      Participants
    title
    PAN: C1D8
  3. denoms
    1. counts
      1. group Id
        OG000
        value
        0
      units
      Participants
    title
    BJB432: C1D1
  4. denoms
    1. counts
      1. group Id
        OG000
        value
        0
      units
      Participants
    title
    BJB432: C1D8
denoms
  1. counts
    1. group Id
      OG000
      value
      8
    units
    Participants
description
CL/F: The apparent total body clearance of drug from the plasma
dispersion Type
Geometric Coefficient of Variation
groups
  1. description
    Participants were administered LBH589 (panobinostat)in combination with bortezomib and dexamethasone 2 weeks on/1 week off.
    id
    OG000
    title
    LBH589 + Bortezomib + Dexamethasone
param Type
GEOMETRIC_MEAN
population Description
PAS: Pharmacokinetic Analysis Set (PAS): The PK analysis set for PAN (PAS-PAN) consisted of all subjects with at least one evaluable PK concentration of PAN. The PK analysis set for BTZ (PAS-BTZ) consisted of all subjects with at least one evaluable PK concentration of BTZ.
reporting Status
POSTED
time Frame
Predose, 0.5h, 1h, 2h, 3h, 4h 8h, 24h 48h post dose
title
Composite PharmacoKinetics (PK) of Panobinostat and Bortezomib: CL/F
type
SECONDARY
unit Of Measure
Litre/hour (L/h)

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice